Olivier Léger Email & Phone Number

Paris, Île-de-France, France

Annecy Area, France

• Agreement for french "Crédit Impôt Recherche" (CIR) for 2017, 2018, 2019, 2020, 2021
• Provide as a service the design of humanization of mouse / rat antibodies using a modernized version of the traditional CDR grafting technique: o Well recognized expertise knowledge in humanization. o Sequence analysis.
• Provide as a service the possibility of the humanized constructs to be synthesized, cloned, expressed, purified and tested using CRO facilities: o Identify project risks at the onset of the program. o Identify and.
• Provide as a service sequence optimization of fully human antibodies to improve developability / manufacturability by germlining and elimination of potentially problematic amino acid single residues or motifs.
• Provide as a service project plan for antibody projects from discovery to preclinical development and oversee if necessary the progression of the project.
• Due diligence and evaluation of antibody technologies.

Lure, Bourgogne-Franche-Comté, France

Paris, Île-de-France, France

Responsible for discovering biotech products for small and large animals in particular monoclonal antibodies to be used in pets for treating skin diseases

Geneva Area, Switzerland

• Antibody engineering processes: sequence optimization for improved manufacturability, affinity maturation by semi-rational design and humanization by CDR-grafting.
• Project team member on internal antibody projects from discovery to preclinical development.
• Project team member on external collaborations on antibody or "nanobody" related projects.
• Due diligence and evaluation of external in-licensing opportunities.
• Line-management responsibilites.
• Group leadership

Geneva Area, Switzerland

• Responsible for the engineering of recombinant fully human antibodies derived from the phage display DiversityTrap platform: NI-0801, anti-human CXCL10 (IP10) and NI-0501, anti-human interferon gamma.
• Responsible for the engineering of recombinant fully human antibodies derived from BMS/Medarex UltiMAb transgenic mouse system: NI-0401, anti-human CD3-epsilon; NI-1401 cross-reactive anti-human IL-17A&F partnered with.
• Humanization by CDR-grafting of mouse antibodies, most noticeably NI-0101, a monoclonal antibody drug candidate targeting Toll-like receptor-4 (TLR4) presently undergoing dosing in a phase I clinical trial.
• Engineering of Fc to enhance binding to human Fc-gamma-Receptor II.
• Project management and line management responsibilities.

Saint Julien En Genevois, France

• Establish an Antibody Engineering group at CIPF whose director was Dr. Jean-Yves Bonnefoy.
• Responsible for the engineering and development of recombinant antibodies for use in human cancer therapy.
• Humanisation by CDR-grafting of an anti-IGF-1 receptor mouse monoclonal antibody, F50035, which has being licensed by Merck & Co.
• Line-managment responsabilites.

Mill Hill, London, UK

• The Antibody Engineering Group led by Mary M. Bendig was established at the MRC Collaborative Centre to exploit MRC-patented technologies for humanisation by CDR-grafting and MRC-CAT-patented technologies for phage.
• Responsible for humanisaton by CDR-grafting of mouse monoclonal antibodies and most noticeably of the anti-alpha4 integrin antibody, Natalizumab, co-marketed by Biogen Idec and Elan as Tysabri for multiple sclerosis.
• Construction and screening of phage antibody libraries derived from the lymph nodes of human cancer patients for anti-tumor cell specific scFvs.
• Line-management responsabilities.

Sutton, United Kingdom

• Gain of new advances in molecular biology techniques related to antibody engineering; PCR-cloning and DNA sequencing of variable genes, construction of scFv formats, expression of recombinant antibody and antibody.

Sutton, Surrey, UK

• Characterization of the serological anti-tumor response to a chemically-induced rat sarcoma; idiotypic network
• Rat hybridoma technology: immunisation of rats via the Peyer's patches, obtention of rat x rat hybridomas
• Antibody characterization; purification by affinity chromatography, SDS-PAGE
• Assay development: radio-immunassays, cellular assays
• Purification, characterization and identification of a chemically-induced tumor antigen in syngeneic rats

Hampstead, London, UK

• Position in the bone marrow transplantation unit headed by Dr. H. Grant Prentice and the research directed by Dr. Malcolm K. Brenner
• Evaluation of the effect of interleukin-2 on the killer cell function of natural killer cells after T-cell depleted bone marrow transplantation

Montpellier, France

• Project was to compare two different techniques of human T-cell depletion from peripheral blood and bone marrow; complement-mediated cytolysis and immunotoxin T101 ricin chain A conjugate-mediated depletion (T101.
• Immunotoxin T101 ricin chain A project headed by Frank K. Jansen and under the supervision of Dr. Jean-Marie Derocq

Doctor Of Philosophy (Ph.D.), Immunology

Title: Immune responses to a rat tumor in relation to the idiotypic network at The Institute of Cancer Research in Sutton, Surrey, UK.

Diplome D'Etudes Approfondies (Dea) De Biologie Santé, Option Immunologie

Immunology course given by professors Marie-Paule and Gérard Lefranc